Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imprime PGG + Pembrolizumab in Advanced Melanoma or TNBC
NCT02981303Phase 2Completed
- Sponsor
- HiberCell
- Start
- Feb 2017
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of odetiglucan in melanoma and triple negative breast cancer (TNBC) (2 cohorts), sponsored by HiberCell. Primary endpoint: Overall Response Rate at 24 months. Started Feb 2017; status: completed.
02
Drugs
odetiglucan
03
Conditions
melanomatriple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02981303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981303.